Parexel (NASDAQ:PRXL) is one of those companies that fall into the category of being large and fairly profitable, but not exactly in the public's eye. The one possible incident that may possibly ring a bell is a 2006 trial by the now-defunct German pharmaceutical company TeGenero, which Parexel ran. As a brief summary, TeGenero's now infamous drug TGN1412 was tested on humans for the first time and led to multiple organ failure in six patients, launching a firestorm in the process, as one would imagine. Granted, this is far into Parexel's past and has little bearing on the massive potential the company has in the coming months.
Parexel belongs to the family of contract research organizations (...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|